Difference between revisions of "Volunteer Assignments and Opportunities"
Jump to navigation
Jump to search
| [unchecked revision] | [unchecked revision] |
| Line 332: | Line 332: | ||
| | | | ||
|- | |- | ||
| − | |Precursor Lymphoid Neoplasms ||'''''Overview'''''|| ||Yassmine Akkari (YA) | + | |Precursor Lymphoid Neoplasms||'''''Overview'''''|| ||Yassmine Akkari (YA) |
| | | | ||
| | | | ||
| Line 396: | Line 396: | ||
| | | | ||
|- | |- | ||
| − | | | + | |Mature B-Cell Neoplasms||'''''Overview'''''|| ||Snehal Patel (SP) |
| | | | ||
| | | | ||
|- | |- | ||
| − | | | + | |Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma||Disease|| ||SP |
| | | | ||
| | | | ||
|- | |- | ||
| − | | | + | | Monoclonal B-cell Lymphocytosis||Disease|| ||SP |
| | | | ||
| | | | ||
|- | |- | ||
| − | | | + | |B-cell Prolymphocytic Leukemia||Disease|| ||SP |
| | | | ||
| | | | ||
|- | |- | ||
| − | | | + | |Splenic Marginal Zone Lymphoma||Disease|| ||SP |
| | | | ||
| | | | ||
|- | |- | ||
| − | | | + | |Hairy Cell Leukemia||Disease|| ||SP |
| | | | ||
| | | | ||
|- | |- | ||
| − | | | + | |Splenic B-cell Lymphoma/Leukemia, Unclassifiable||'''''Overview'''''|| ||SP |
| | | | ||
| | | | ||
|- | |- | ||
| − | | | + | | Splenic Diffuse Red Pulp Small B-cell Lymphoma||Disease|| ||SP |
| | | | ||
| | | | ||
|- | |- | ||
| − | | | + | | Hairy Cell Leukemia Variant||Disease|| ||SP |
| | | | ||
| | | | ||
|- | |- | ||
| − | | | + | |Lymphoplasmacytic Lymphoma||Disease|| ||SP |
| | | | ||
| | | | ||
|- | |- | ||
| − | | | + | | Waldenstrom Macroglobulinemia||Disease|| ||SP |
| | | | ||
| | | | ||
|- | |- | ||
| − | | | + | |IgM Monoclonal Gammopathy of Undetermined Significance||Disease|| ||SP |
| | | | ||
| | | | ||
|- | |- | ||
| − | | | + | |Heavy Chain Diseases||'''''Overview'''''|| ||SP |
| | | | ||
| | | | ||
|- | |- | ||
| − | | | + | | Mu Heavy Chain Disease||Disease|| ||SP |
| | | | ||
| | | | ||
|- | |- | ||
| − | | | + | | Gamma Heavy Chain Disease||Disease|| ||SP |
| | | | ||
| | | | ||
|- | |- | ||
| − | | | + | | Alpha Heavy Chain Disease||Disease|| ||SP |
| | | | ||
| | | | ||
Revision as of 17:29, 21 May 2020
| Disease | Page Type | Author | Associate Editor | Author Content (Pending or Complete) | Editor Reviewed (Date) |
|---|---|---|---|---|---|
| Myeloproliferative Neoplasms (MPN) | Overview | Fabiola Quintero-Rivera (FQR) | |||
| Chronic Myeloid Leukemia (CML), BCR-ABL1-Positive | Disease | FQR | |||
| Chronic Neutrophilic Leukemia (CNL) | Disease | FQR | |||
| Polycythaemia Vera (PV) | Disease | FQR | |||
| Primary Myelofibrosis (PMF) | Disease | FQR | |||
| Essential Thrombocythaemia (ET) | Disease | FQR | |||
| Chronic Eosinophilic Leukemia, Not Otherwise Specified | Disease | FQR | |||
| Myeloproliferative Neoplasm (MPN), Unclassifiable | Disease | FQR | |||
| Mastocytosis | Overview | FQR | |||
| Cutaneous Mastocytosis | Disease | FQR | |||
| Systemic Mastocytosis | Disease | FQR | |||
| Mast Cell Sarcoma | Disease | FQR | |||
| Myeloid/Lymphoid Neoplasms with Eosinophilia and Rearrangement of PDGFRA, PDGFRB or FGFR1, or with PCM1-JAK2 | Overview | FQR | |||
| Myeloid/Lymphoid Neoplasms with PDGFRA Rearrangement | Disease | FQR | |||
| Myeloid/Lymphoid Neoplasms with PDGFRB Rearrangement | Disease | FQR | |||
| Myeloid/Lymphoid Neoplasms with FGFR1 Rearrangement | Disease | FQR | |||
| Myeloid/Lymphoid Neoplasms with PCM1-JAK2 | Disease | FQR | |||
| Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN) | Overview | FQR | |||
| Chronic Myelomonocytic Leukemia (CMML) | Disease | FQR | |||
| Atypical Chronic Myeloid Leukemia (aCML), BCR-ABL1 Negative | Disease | FQR | |||
| Juvenile Myelomonocytic Leukemia (JMML) | Disease | FQR | |||
| Myelodysplastic/Myeloproliferative Neoplasms with Ring Sideroblasts and Thrombocytosis (MDS/MPN-RS-T) | Disease | FQR | |||
| Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN), Unclassifiable | Disease | FQR | |||
| Myelodysplastic Syndromes (MDS) | Overview | FQR | |||
| Myelodysplastic Syndrome (MDS) with Single Lineage Dysplasia | Disease | FQR | |||
| Myelodysplastic Syndrome with Ring Sideroblasts (MDS-RS) | Disease | FQR | |||
| Myelodysplastic Syndrome with Ring Sideroblasts and Multilineage Dysplasia | Disease | FQR | |||
| Myelodysplastic syndrome with multilineage dysplasiaMyelodysplastic Syndrome (MDS) with Multilineage Dysplasia | Disease | FQR | |||
| Myelodysplastic Syndrome (MDS) with Excess Blasts | Disease | FQR | |||
| Myelodysplastic Syndrome (MDS) with Isolated del(5q) | Disease | FQR | |||
| Myelodysplastic Syndrome (MDS), Unclassifiable | Disease | FQR | |||
| Refractory Cytopenia of Childhood | Disease | FQR | |||
| Acute Myeloid Leukemia (AML) and Related Precursor Neoplasms | Overview | Jennelle Hodge (JH) | |||
| Myeloid Neoplasms with Germline Predisposition | Overview | JH | |||
| Acute Myeloid Leukaemia with Germline CEBPA Mutation | Disease | JH | |||
| Myeloid Neoplasms with Germline DDX41 Mutation | Disease | JH | |||
| Myeloid Neoplasms with Germline RUNX1 Mutation | Disease | JH | |||
| Myeloid Neoplasms with Germline ANKRD26 Mutation | Disease | JH | |||
| Myeloid Neoplasms with Germline ETV6 Mutation | Disease | JH | |||
| Myeloid Neoplasms with Germline GATA2 Mutation | Disease | JH | |||
| Acute Myeloid Leukemia (AML) with Recurrent Genetic Abnormalities | Overview | JH | |||
| Acute Myeloid Leukemia (AML) with t(8;21)(q22;q22.1); RUNX1-RUNX1T1 | Disease | JH | |||
| Acute Myeloid Leukemia with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11 | Disease | JH | |||
| Acute Promyelocytic Leukemia (APL) with PML-RARA | Disease | JH | |||
| Acute Myeloid Leukemia (AML) with t(9;11)(p21.3;q23.3); KMT2A-MLLT3 | Disease | JH | |||
| Acute Myeloid Leukemia (AML) with t(6;9)(p23;q34.1); DEK-NUP214 | Disease | JH | |||
| Acute Myeloid Leukemia (AML) with inv(3)(q21.3q26.2) or t(3;3)(q21.3;q26.2);GATA2, MECOM | Disease | JH | |||
| Acute Myeloid Leukemia (AML) Megakaryoblastic with t(1;22)(p13.3;q13.1);RBM15-MKL1 | Disease | JH | |||
| Acute Myeloid Leukemia (AML) with BCR-ABL1 | Disease | JH | |||
| Acute Myeloid Leukemia (AML) with Mutated NPM1 | Disease | JH | |||
| Acute Myeloid Leukemia (AML) with Biallelic Mutations of CEBPA | Disease | JH | |||
| Acute Myeloid Leukemia (AML) with Mutated RUNX1 | Disease | JH | |||
| Acute Myeloid Leukemia (AML) with Myelodysplasia-Related Changes | Disease | JH | |||
| Therapy-Related Myeloid Neoplasms | Disease | JH | |||
| Acute Myeloid Leukemia (AML), Not Otherwise Specified | Overview | JH | |||
| Acute Myeloid Leukemia (AML) with Minimal Differentiation | Disease | JH | |||
| Acute Myeloid Leukemia (AML) without Maturation | Disease | JH | |||
| Acute Myeloid Leukemia (AML) with Maturation | Disease | JH | |||
| Acute Myelomonocytic Leukemia | Disease | JH | |||
| Acute Monoblastic and Monocytic Leukemia | Disease | JH | |||
| Pure Erythroid Leukemia | Disease | JH | |||
| Acute Megakaryoblastic Leukemia (AMKL) | Disease | JH | |||
| Acute Basophilic Leukemia | Disease | JH | |||
| Acute Panmyelosis with Myelofibrosis | Disease | JH | |||
| Myeloid Sarcoma | Disease | JH | |||
| Myeloid Proliferations Associated with Down Syndrome | Overview | JH | |||
| Transient Abnormal Myelopoiesis (TAM) Associated with Down Syndrome | Disease | JH | |||
| Myeloid Leukemia Associated with Down Syndrome | Disease | JH | |||
| Blastic Plasmacytoid Dendritic Cell Neoplasm | Disease | JH | |||
| Acute Leukemias of Ambiguous Lineage | Overview | JH | |||
| Acute Undifferentiated Leukemia | Disease | JH | |||
| Mixed Phenotype Acute Leukemia (MPAL) with t(9;22)(q34.1;q11.2); BCR-ABL1 | Disease | JH | |||
| Mixed Phenotype Acute Leukemia (MPAL) with t(v;11q23.3); KMT2A Rearranged | Disease | JH | |||
| Mixed Phenotype Acute Leukemia (MPAL), B/Myeloid, Not Otherwise Specified | Disease | JH | |||
| Mixed Phenotype Acute Leukemia (MPAL), T/Myeloid, Not Otherwise Specified | Disease | JH | |||
| ??Mixed-Phenotype Acute Leukaemia, Not Otherwise Specified (NOS), Rare Types | Disease | JH | |||
| ??Acute Leukaemias of Ambiguous Lineage, Not Otherwise Specified (NOS) | Disease | JH | |||
| Precursor Lymphoid Neoplasms | Overview | Yassmine Akkari (YA) | |||
| B-Lymphoblastic Leukemia/Lymphoma with Recurrent Genetic Abnormalities | Overview | YA | |||
| B-Lymphoblastic Leukemia/Lymphoma with t(9;22)(q34.1;q11.2); BCR-ABL1 | Disease | YA | |||
| B-Lymphoblastic Leukemia/Lymphoma with t(v;11q23.3); KMT2A-Rearranged | Disease | YA | |||
| B-Lymphoblastic Leukemia/Lymphoma with t(12;21)(p13.2;q22.1); ETV6-RUNX1 | Disease | YA | |||
| B-Lymphoblastic Leukemia/Lymphoma with Hyperdiploidy | Disease | YA | |||
| B-Lymphoblastic Leukemia/Lymphoma with Hypodiploidy | Disease | YA | |||
| B-Lymphoblastic Leukemia/Lymphoma with t(5;14)(q31.1;q32.1); IGH/IL3 | Disease | YA | |||
| B-Lymphoblastic Leukemia/Lymphoma with t(1;19)(q23;p13.3); TCF3-PBX1 | Disease | YA | |||
| B-Lymphoblastic Leukemia/Lymphoma, BCR-ABL1-Like | Disease | YA | |||
| B-Lymphoblastic Leukemia/Lymphoma with iAMP21 | Disease | YA | |||
| B-Lymphoblastic Leukemia/Lymphoma, Not Otherwise Specified | Disease | YA | |||
| T-Lymphoblastic Leukemia/Lymphoma | Overview | YA | |||
| Early T-Cell Precursor Lymphoblastic Leukemia | Disease | YA | |||
| NK-Lymphoblastic Leukemia/Lymphoma | Disease | YA | |||
| Mature B-Cell Neoplasms | Overview | Snehal Patel (SP) | |||
| Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | Disease | SP | |||
| Monoclonal B-cell Lymphocytosis | Disease | SP | |||
| B-cell Prolymphocytic Leukemia | Disease | SP | |||
| Splenic Marginal Zone Lymphoma | Disease | SP | |||
| Hairy Cell Leukemia | Disease | SP | |||
| Splenic B-cell Lymphoma/Leukemia, Unclassifiable | Overview | SP | |||
| Splenic Diffuse Red Pulp Small B-cell Lymphoma | Disease | SP | |||
| Hairy Cell Leukemia Variant | Disease | SP | |||
| Lymphoplasmacytic Lymphoma | Disease | SP | |||
| Waldenstrom Macroglobulinemia | Disease | SP | |||
| IgM Monoclonal Gammopathy of Undetermined Significance | Disease | SP | |||
| Heavy Chain Diseases | Overview | SP | |||
| Mu Heavy Chain Disease | Disease | SP | |||
| Gamma Heavy Chain Disease | Disease | SP | |||
| Alpha Heavy Chain Disease | Disease | SP | |||
| Example | Example | Example | |||
| Example | Example | Example | |||
| Example | Example | Example | |||
| Example | Example | Example | |||
| Example | Example | Example | |||
| Example | Example | Example | |||
| Example | Example | Example | |||
| Example | Example | Example | |||
| Example | Example | Example | |||
| Example | Example | Example | |||
| Example | Example | Example | |||
| Example | Example | Example | |||
| Example | Example | Example | |||
| Example | Example | Example | |||
| Example | Example | Example | |||
| Example | Example | Example | |||
| Example | Example | Example | |||
| Example | Example | Example | |||
| Example | Example | Example | |||
| Example | Example | Example | |||
| Example | Example | Example | |||
| Example | Example | Example | |||
| Example | Example | Example | |||
| Example | Example | Example | |||
| Example | Example | Example | |||
| Example | Example | Example | |||
| Example | Example | Example | |||
| Example | Example | Example | |||
| Example | Example | Example | |||
| Example | Example | Example | |||
| Example | Example | Example | |||
| Example | Example | Example | |||
| Example | Example | Example | |||
| Example | Example | Example | |||
| Example | Example | Example | |||
| Example | Example | Example | |||
| Example | Example | Example | |||
| Example | Example | Example | |||
| Example | Example | Example | |||
| Example | Example | Example | |||
| Example | Example | Example | |||
| Example | Example | Example | |||
| Example | Example | Example | |||
| Example | Example | Example | |||
| Example | Example | Example | |||
| Example | Example | Example | |||
| Example | Example | Example | |||
| Example | Example | Example | |||
| Example | Example | Example | |||
| Example | Example | Example | |||
| Example | Example | Example | |||
| Example | Example | Example | |||
| Example | Example | Example | |||
| Example | Example | Example | |||
| Example | Example | Example | |||
| Example | Example | Example | |||
| Example | Example | Example | |||
| Example | Example | Example | |||
| Example | Example | Example | |||
| Example | Example | Example | |||
| Example | Example | Example | |||
| Example | Example | Example | |||
| Example | Example | Example | |||
| Example | Example | Example | |||
| Example | Example | Example | |||
| Example | Example | Example | |||
| Example | Example | Example | |||
| Example | Example | Example | |||
| Example | Example | Example | |||
| Example | Example | Example | |||
| Example | Example | Example | |||
| Example | Example | Example | |||
| Example | Example | Example | |||
| Example | Example | Example | |||
| Example | Example | Example | |||
| Example | Example | Example | |||
| Example | Example | Example | |||
| Example | Example | Example | |||
| Example | Example | Example | |||
| Example | Example | Example | |||
| Example | Example | Example | |||
| Example | Example | Example | |||
| Example | Example | Example | |||
| Example | Example | Example | |||
| Example | Example | Example | |||
| Example | Example | Example | |||
| Example | Example | Example | |||
| Example | Example | Example | |||
| Example | Example | Example | |||
| Example | Example | Example | |||
| Example | Example | Example | |||
| Example | Example | Example | |||
| Example | Example | Example | |||
| Example | Example | Example | |||
| Example | Example | Example | |||
| Example | Example | Example | |||
| Example | Example | Example | |||
| Example | Example | Example | |||
| Example | Example | Example | |||
| Example | Example | Example | |||
| Example | Example | Example | |||
| Example | Example | Example | |||
| Example | Example | Example | |||
| Example | Example | Example | |||
| Example | Example | Example | |||
| Example | Example | Example | |||
| Example | Example | Example | |||
| Example | Example | Example | |||
| Example | Example | Example | |||
| Example | Example | Example | |||
| Example | Example | Example | |||
| Example | Example | Example | |||
| Example | Example | Example | |||
| Example | Example | Example | |||
| Example | Example | Example | |||
| Example | Example | Example | |||
| Example | Example | Example | |||
| Example | Example | Example | |||
| Example | Example | Example | |||
| Example | Example | Example | |||
| Example | Example | Example | |||
| Example | Example | Example | |||
| Example | Example | Example | |||
| Example | Example | Example | |||
| Example | Example | Example | |||
| Example | Example | Example | |||
| Example | Example | Example | |||
| Example | Example | Example | |||
| Example | Example | Example | |||
| Example | Example | Example | |||
| Example | Example | Example | |||
| Example | Example | Example | |||
| Example | Example | Example | |||
| Example | Example | Example | |||
| Example | Example | Example | |||
| Example | Example | Example | |||
| Example | Example | Example |